Literature DB >> 2038982

Trends of HIV-1 risk reduction among initiates into intravenous drug use 1982-1987.

D Vlahov1, J C Anthony, D Celentano, L Solomon, N Chowdhury.   

Abstract

To assess how injection practices may have changed during the course of the AIDS epidemic, active intravenous drug users (IVDUs) recruited from the community were asked to report year of first injection as well as specific details about the first 3 months after initial injection: frequencies of injection, using sterile needles, sharing needles and other equipment. For the analysis, the users were sorted into successive cohorts of initiation (by year of first injection), and tests for trends were completed using Mantel-Haenszel statistics. Among the 421 IVDUs who reported first injection between 1982 and 1987, the use of new sterile needles to self-administer drugs increased (p less than .05) along with its corollary behavior (i.e., using equipment one is sure that no one else had used before). Conversely, there was a decrease in the proportion of those who always used equipment previously used by another IVDU (p less than .05) and a decrease in the number of needle-sharing partners (p less than .01). Over the 6 years, heroin as first drug decreased and cocaine increased (p less than .01). Although these data are from a cross-sectional interview study, they suggest a shift toward lower risk practices among new IVDUs between 1982 and 1987. The shift from heroin to cocaine is compatible with other evidence on the cocaine epidemic.

Entities:  

Mesh:

Year:  1991        PMID: 2038982     DOI: 10.3109/00952999108992808

Source DB:  PubMed          Journal:  Am J Drug Alcohol Abuse        ISSN: 0095-2990            Impact factor:   3.829


  21 in total

1.  HIV transmission and the cost-effectiveness of methadone maintenance.

Authors:  G S Zaric; P G Barnett; M L Brandeau
Journal:  Am J Public Health       Date:  2000-07       Impact factor: 9.308

2.  Factors associated with adolescent initiation of injection drug use.

Authors:  C M Fuller; D Vlahov; A M Arria; D C Ompad; R Garfein; S A Strathdee
Journal:  Public Health Rep       Date:  2001       Impact factor: 2.792

Review 3.  Microbial infections, immunomodulation, and drugs of abuse.

Authors:  Herman Friedman; Catherine Newton; Thomas W Klein
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

4.  Effects of race, neighborhood, and social network on age at initiation of injection drug use.

Authors:  Crystal M Fuller; Luisa N Borrell; Carl A Latkin; Sandro Galea; Danielle C Ompad; Steffanie A Strathdee; David Vlahov
Journal:  Am J Public Health       Date:  2005-04       Impact factor: 9.308

Review 5.  Drugs of abuse, immune modulation, and AIDS.

Authors:  Guy A Cabral
Journal:  J Neuroimmune Pharmacol       Date:  2006-06-28       Impact factor: 4.147

6.  The relationship between discrimination and high-risk social ties by race/ethnicity: examining social pathways of HIV risk.

Authors:  Natalie D Crawford; Sandro Galea; Chandra L Ford; Carl Latkin; Bruce G Link; Crystal Fuller
Journal:  J Urban Health       Date:  2014-02       Impact factor: 3.671

7.  ADHD as a risk factor for early onset and heightened adult problem severity of illicit substance use: an accelerated gateway model.

Authors:  Eugene M Dunne; Lauren E Hearn; Jonathan J Rose; William W Latimer
Journal:  Addict Behav       Date:  2014-07-10       Impact factor: 3.913

8.  IV drug users: changes in risk behaviour according to HIV status in a national survey in Spain.

Authors:  M Delgado-Rodríguez; L dé lá Fuente; M J Bravo; P Lardelli; G Barrio
Journal:  J Epidemiol Community Health       Date:  1994-10       Impact factor: 3.710

9.  Correlates of needle sharing among injection drug users.

Authors:  W Mandell; D Vlahov; C Latkin; M Oziemkowska; S Cohn
Journal:  Am J Public Health       Date:  1994-06       Impact factor: 9.308

10.  The consistency of self-reported HIV risk behavior among injection drug users.

Authors:  K McElrath; D D Chitwood; D K Griffin; M Comerford
Journal:  Am J Public Health       Date:  1994-12       Impact factor: 9.308

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.